Non−Small-cell Lung Cancer (NSCLC) Therapeutic Profile II

Casandra

Casandra Test Code LC27478Version 1 (DRAFT)

Performing Lab

Lab LabcorpLab Test ID 388103

Non−Small-cell Lung Cancer (NSCLC) Therapeutic Profile II

Clinical Use

Use

Non−small-cell lung cancer (NSCLC) is the leading cause of death from cancer in both men and women in the US. A subgroup of NSCLC patients has shown clinical responsiveness to the epidermal growth factor receptor (EGFR) inhibitors gefitinib (Iressa®) and erlotinib (Tarceva®). In the majority of patients with highly responsive tumors, the tumor contains somatic mutations within the EGFR tyrosine kinase domain. The presence of a somatic EGFR mutation is significantly associated with deferential responsiveness or resistance to gefitinib and erlotinib, and is strongly predictive of prolonged survival in NSCLC patients.

Special Instructions

Not provided.

Limitations

The EGFR test is designed to detect mutations in exons 18, 19, 20, and 21 of the EGFR gene. These mutations account for >99% of all reported EGFR mutations in NSCLC patients. The KRAS test is designed to detect mutations in exons 2, 3, and 4 of the KRAS gene. Samples with results reported as "no mutation detected" may harbor mutations that are not detected by the assay.

Test Details